NCT02321839View on ClinicalTrials.gov

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Intraviteal Ranibizumab 0.5mg

Intraviteal Ranibizumab 0.5mg

Trial Locations (2)

460-0008

Sugita Eye Hospital, Nagoya

467-8602

Nagoya City Univsersity, Nagoya

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Nagoya City University

OTHER